

| JOURNAL | TITLE | PMID | CITATION |
|--------------------------|---|--------------------------|---|
| <i>Lancet</i> | Use of once-weekly insulins for type 1 diabetes. | 40651815 | Russell-Jones D, Klonoff DC. Use of once-weekly insulins for type 1 diabetes. <i>Lancet</i> . 2025 Jul 12; 406(10499):130. |
| <i>Lancet Respir Med</i> | Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. | 40683298 | Guglielmetti L, Khan U, Velázquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektasov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD, endTB-Q Clinical Trial Team. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. <i>Lancet Respir Med</i> . 2025 Jul 16. |
| <i>Lancet Respir Med</i> | Evaluating the generalisability of formulas used to set tidal volumes in mechanically ventilated patients: an observational, multicohort, retrospective study. | 40680763 | Sarma A, Sullivan KM, Baugh AD, Bhakta NR, Calfee CS. Evaluating the generalisability of formulas used to set tidal volumes in mechanically ventilated patients: an observational, multicohort, retrospective study. <i>Lancet Respir Med</i> . 2025 Jul 15. |
| <i>Lancet Infect Dis</i> | Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. | 40645198 | Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, Sebe M, Rassool M, Wallis RS, Ntinginya N, Liyoyo A, Mbeya B, Wagnerberger L, Zumba T, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut JA, Aarnoutse R, McHugh TD, Wildner L, Boeree MJ, Geiter L, Cho YL, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. <i>Lancet Infect Dis</i> . 2025 Jul 08. |
| <i>Lancet Infect Dis</i> | Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. | 40645196 | Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, Wallis RS, Ntinginya N, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Stoycheva K, Zumba T, Noreña I, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut J, Aarnoutse RE, McHugh TD, Wildner L, Boeree M, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, PanACEA consortium. |

| | | | |
|----------------------------------|--|--------------------------|--|
| | | | Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. <i>Lancet Infect Dis.</i> 2025 Jul 08. |
| <i>J Clin Oncol</i> | RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). | 40627813 | Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, LebbÃ© C, Gaudy-Marqueste C, Middleton MR, Skolariki A, Samson A, Chesney JA, VanderWalde AM, Zakharia Y, Harrington KJ, Appleton E, Bommarreddy PK, Zhu J, Viana M, Hou JW, Coffin RS, Robert C. RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). <i>J Clin Oncol.</i> 2025 Jul 08; 101200JCO2501346. |
| <i>Am J Respir Crit Care Med</i> | Treatment with Allogenic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multi-Center, Phase 2b Clinical Trial (STAT). | 40728562 | Matthay MA, Zhou H, Sarma A, Alipanah-Lechner N, Hendrickson C, Kornblith LZ, Schreiber M, Zonies D, Khan A, Robinson B, Johnson NJ, Ware LB, Guillaumondegui O, Casey J, Moore L, Patel B, Kao L, Wade CE, Fox E, Cox C, Khawanja F, Aguillon Prada R, Hossri S, Callcut R, Albertson T, Delucchi KL, McMillan M, Langelier CR, Pati S, McKenna DH, Leroux C, Calfee CS, Liu KD. Treatment with Allogenic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multi-Center, Phase 2b Clinical Trial (STAT). <i>Am J Respir Crit Care Med.</i> 2025 Jul 29. |
| <i>Nat Commun</i> | Characterizing trachoma elimination using serology. | 40593530 | Kamau E, Ante-Testard PA, Gwyn S, Blumberg S, Abdalla Z, Aiemyjoy K, Amza A, Aragie S, Arzika AM, Awoussi MS, Bailey RL, Butcher R, Callahan EK, Chaima D, Dawed AA, DÃaz MIS, Domingo AS, Drakeley C, Elshafie BE, Emerson PM, Fornace K, Gass K, Goodhew EB, Hammou J, Harding-Esch EM, Hooper PJ, Kadri B, Kalua K, Kanyi S, Kasubi M, Kello AB, Ko R, Lammie PJ, Lescano AG, Maliki R, Masika MP, Migchelsen SJ, Nassirou B, Nesemann JM, Parameswaran N, Pomat W, Renneker KK, Roberts C, Rymil P, Sata E, Senyonjo L, Seife F, Sillah A, Sokana O, Srivathsan A, Tadesse Z, Taleo F, Taylor EM, Tekeraoi R, Togbey K, West SK, Wickens K, William T, Wittberg DM, Yeboah-Manu D, Youbi M, Zeru T, Keenan JD, Lietman TM, Solomon AW, Nash SD, Martin DL, Arnold BF. Characterizing trachoma elimination using serology. <i>Nat Commun.</i> 2025 Jul 01; 16(1):5545. |
| <i>Nat Commun</i> | Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa. | 40593655 | Phillips A, Smith J, Bansi-Matharu L, Sikwese K, Kityo C, Flexner C, Vitoria M, Ford N, Doherty M, Panos Z, Ripin D, Hickey M, Havlir D, Gandhi M, Reid M, Revill P. Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV |

| | | | |
|------------------------------|--|--------------------------|---|
| | | | treatment in Africa. Nat Commun. 2025 Jul 01; 16(1):5760. |
| <i>JCI Insight</i> | MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury. | 40608426 | Pickering H, Alipanah-Lechner N, Chen E, Duchon D, Maecker HT, Kim-Schulze S, Montgomery RR, Cotsapas C, Steen H, Krammer F, Langelier CR, Levy O, Baden LR, Melamed E, Ehrlich LI, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higueta NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Erle DJ, Schaenman J, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Roupheal N, Altman MC, Bosinger SE, Eckalbar WL, Network I, Calfee CS, Aguilar OA, Reed EF, Greenland JR, Calabrese DR. MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury. JCI Insight. 2025 Jul 03. |
| <i>Blood</i> | Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. | 40663785 | Brooks TR, Zabor EC, Bedelu Y, Yang X, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A, Hernandez-Ilizaliturri FJ, Chinyengetere F, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025 Jul 15. |
| <i>J Am Med Inform Assoc</i> | Differences in Physician EHR Use by Telemedicine Intensity: Evidence from Two Academic Medical Centers. | 40646683 | Kim S, Thombly R, Eiden E, Lou SS, Adler-Milstein J, Kannampallil T, Holmgren AJ. Differences in Physician EHR Use by Telemedicine Intensity: Evidence from Two Academic Medical Centers. J Am Med Inform Assoc. 2025 Jul 11. |
| <i>Am J Hematol</i> | Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. | 40600589 | Miller CR, Huang Y, Allan JN, Bhat SA, Bond D, Brander D, Byrd JC, Chavez J, Chong E, Danilov A, Dowling MR, Dvorak-Kornaus K, Hampel PJ, Ho C, Islam P, Malakhov N, Matasar M, Miller S, Parikh SA, Rabe KG, Rhodes JM, Roeker LE, Rogers KA, Saha A, Skarbnik A, Scott H, Schade J, Shadman M, Shouse G, Stephens DM, Thompson MC, Thompson PA, Wang Y, Woyach JA, Yano M, Omer Z, Kittai AS. Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. Am J Hematol. 2025 Jul 02. |
| <i>J Int AIDS Soc</i> | A prospective cohort study of the SEARCH integrated HIV/hypertension community | 40622370 | Hickey MD, Owaraganise A, Ogachi S, Sunday H, Aoko C, Sang N, Agengo G, Kabami J, Kakande E, Mugoma EW, Schwab J, Sutter N, Black D, Muiru A, Chamie G, Petersen ML, Balzer LB, Bukusi EA, Havlir |

| | | | |
|--------------------------------------|--|--------------------------|---|
| | health worker-led intervention in rural Kenya and Uganda. | | DV, Kanya MR, Ayieko J. A prospective cohort study of the SEARCH integrated HIV/hypertension community health worker-led intervention in rural Kenya and Uganda. <i>J Int AIDS Soc.</i> 2025 Jul; 28 Suppl 3(Suppl 3):e26500. |
| <i>Am J Respir Cell Mol Biol</i> | Multi-omic and Single-Cell Approaches for Elucidating Cell Biology and Pathobiology of Lung Disease. | 40700713 | Sarma A, Sun X, Sucre J, Hong J, Medzikovic L, Jakubzick CV, Li X, Zemans RL, Singer BD. Multi-omic and Single-Cell Approaches for Elucidating Cell Biology and Pathobiology of Lung Disease. <i>Am J Respir Cell Mol Biol.</i> 2025 Jul 23. |
| <i>J Gerontol A Biol Sci Med Sci</i> | Loop diuretics and subsequent use of urinary symptom medications in older adults: evaluation of a possible prescribing cascade. | 40668217 | Growdon ME, Jing B, Deardorff WJ, Morris EJ, Boscardin WJ, Blank LJ, Bongiovanni T, Boockvar KS, Steinman MA. Loop diuretics and subsequent use of urinary symptom medications in older adults: evaluation of a possible prescribing cascade. <i>J Gerontol A Biol Sci Med Sci.</i> 2025 Jul 16. |
| <i>Diabetes Technol Ther</i> | Early Stages of Automated Insulin Delivery. | 40590745 | Zisser H, Hovorka R, Basu A, Battelino T, Boughton CK, Breton MD, Buckingham BA, Brown SA, CherÅ±avsky DR, Dassau E, DeBoer MD, Doyle FJ, Ekhlaspour L, Fabris C, Forlenza GP, Haidar A, Klonoff DC, Kovatchev B, Kowalski AJ, Levy CJ, Kudva YC, Maahs DM, Phillip M, Renard E, Russell SJ, Shah VN, Steil GM, Wadwa RP, Weinzimer SA. Early Stages of Automated Insulin Delivery. <i>Diabetes Technol Ther.</i> 2025 Jul; 27(S3):S33-S47. |
| <i>Diabetes Technol Ther</i> | Registration and Real-Life Studies on Automated Insulin Delivery Systems. | 40590747 | Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. <i>Diabetes Technol Ther.</i> 2025 Jul; 27(S3):S48-S59. |
| <i>J Antimicrob Chemother</i> | Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. | 40613338 | Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, NoreÅ±a I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium . Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. <i>J Antimicrob Chemother.</i> 2025 Jul 04. |
| <i>J Am Med Dir Assoc</i> | A Multi-Outcome Prognostic Model for Community-Dwelling Older Adults Admitted to Skilled Nursing Facilities for Post-Acute Care. | 40659050 | Deardorff WJ, Gan S, Jing B, Boscardin WJ, Smith AK, Lee SJ. A Multi-Outcome Prognostic Model for Community-Dwelling Older Adults Admitted to Skilled Nursing Facilities for Post-Acute Care. <i>J Am Med Dir Assoc.</i> 2025 Jul 11; 105775. |
| <i>Am J Public Health</i> | Common Data Element (CDE) Success from Community-Engagement Not Mandates: If | 40561407 | Gansky SA, Cheng AC, Mendhe D, Chavez A, Yeh HC, Lanier K, Brown W, Hersch DE, Huang ES, Enders FT, Phelan SM. Common Data Element (CDE) Success from Community-Engagement Not Mandates: If You |

| | | | |
|------------------------------------|---|--------------------------|--|
| | You Build It [Data Warehouse], Will They [Participants] Come? | | Build It [Data Warehouse], Will They [Participants] Come? Am J Public Health. 2025 Jul; 115(S2):S110-S115. |
| <i>Am J Public Health</i> | The Health Equity Action Network Research Coordinating Center Facilitates Meaningful Community Engagement to Promote Health Equity. | 40561402 | Pardo EN, Joseph G, Rojo EM, Beyene S, Taylor KD, Charlebois ED, Gansky SA, Rhoads KF. The Health Equity Action Network Research Coordinating Center Facilitates Meaningful Community Engagement to Promote Health Equity. Am J Public Health. 2025 Jul; 115(S2):S98-S103. |
| <i>J Acquir Immune Defic Syndr</i> | Outcomes of Rapid Restart among People with Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco. | 40704911 | Salazar J, Coffey S, Bloome J, Hickey MD, Fleming L, Franco S, Suarez A, Havlir D, Saucedo JA, Gandhi M, Christopoulos KA. Outcomes of Rapid Restart among People with Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco. J Acquir Immune Defic Syndr. 2025 Jul 24. |
| <i>JACC Clin Electrophysiol</i> | Phenotyping of Mitral Valve Prolapse Without Severe Mitral Regurgitation Using Electrocardiographic and Echocardiographic Data. | 40673846 | Tastet L, Ansari MU, Barrios JP, Cristin L, Jhawar R, Rich A, Bibby D, Fang Q, Arya F, Tison GH, Delling FN. Phenotyping of Mitral Valve Prolapse Without Severe Mitral Regurgitation Using Electrocardiographic and Echocardiographic Data. JACC Clin Electrophysiol. 2025 Jul 01. |
| <i>BMJ Qual Saf</i> | Evaluation of the accuracy and safety of machine translation of patient-specific discharge instructions: a comparative analysis. | 40633961 | Kong M, Fernandez A, Bains J, Milisavljevic A, Brooks KC, Shanmugam A, Avilez L, Li J, Honcharov V, Yang A, Khoong EC. Evaluation of the accuracy and safety of machine translation of patient-specific discharge instructions: a comparative analysis. BMJ Qual Saf. 2025 Jul 09. |
| <i>J Gen Intern Med</i> | Sex Differences in Management of Hypertension in US Ambulatory Practice. | 40601192 | Hargrave-Bouagnon AS, Begna H, Lipinsky DeGette R, Wistar E, Schwarz EB. Sex Differences in Management of Hypertension in US Ambulatory Practice. J Gen Intern Med. 2025 Jul 02. |
| <i>Obstet Gynecol</i> | National Trends in Prepregnancy Cardiometabolic Risk and Counseling: An Analysis of the Pregnancy Risk Assessment Monitoring System, 2016-2022. | 40609091 | McLaughlin MM, Lee C, Ghaffari N, Gonzalez Velez JM, Beatty AL. National Trends in Prepregnancy Cardiometabolic Risk and Counseling: An Analysis of the Pregnancy Risk Assessment Monitoring System, 2016-2022. Obstet Gynecol. 2025 Jul 03. |
| <i>J Diabetes Sci Technol</i> | Early Stages of Automated Insulin Delivery. | 40590463 | Zisser H, Hovorka R, Basu A, Battelino T, Boughton CK, Breton MD, Buckingham BA, Brown SA, CherÅ±avsky DR, Dassau E, DeBoer MD, Doyle FJ, Ekhlaspour L, Fabris C, Forlenza GP, Haidar A, Klonoff DC, Kovatchev B, Kowalski AJ, Levy CJ, Kudva YC, Maahs DM, Phillip M, Renard E, Russell SJ, Shah VN, Steil GM, Wadwa RP, Weinzimer SA. Early Stages of Automated Insulin Delivery. J Diabetes Sci Technol. 2025 Jul; 19(4):908-923. |
| <i>J Diabetes Sci Technol</i> | Registration and Real-Life Studies on Automated Insulin Delivery Systems. | 40590465 | Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 Jul; 19(4):924-936. |

| | | | |
|----------------------------|--|--------------------------|--|
| <i>BMC Med Educ</i> | Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement. | 40604726 | Jones BLH, L ³ pez L, Garg M. Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement. <i>BMC Med Educ</i> . 2025 Jul 02; 25(1):995. |
| <i>Physiol Rep</i> | Left ventricular concentric remodeling is highly common among veterans deployed to Southwest Asia and is associated with impaired exercise performance. | 40631357 | Cassady SJ, Abitante TJ, Pappas GG, Alexander T, Falvo MJ, Post-Deployment Cardiopulmonary Evaluation Network. Left ventricular concentric remodeling is highly common among veterans deployed to Southwest Asia and is associated with impaired exercise performance. <i>Physiol Rep</i> . 2025 Jul; 13(13):e70445. |
| <i>Med Educ</i> | Integrating asynchronous trauma-informed care into preclinical education. | 40626387 | Ezenwugo S, Culver J, Iacopetti CL, Connor DM. Integrating asynchronous trauma-informed care into preclinical education. <i>Med Educ</i> . 2025 Jul 08. |
| <i>Contemp Clin Trials</i> | Designing a response-over-continuous-intervention (ROCI) randomised trial: Implementation in the Phase 2C part (duration ranging) of the PARADIGM4TB trial. | 40645367 | Pham TM, Crook AM, Rolfe K, Phillips PPJ, Dufault SM, Quartagno M, UNITE4TB Work Package 2. Designing a response-over-continuous-intervention (ROCI) randomised trial: Implementation in the Phase 2C part (duration ranging) of the PARADIGM4TB trial. <i>Contemp Clin Trials</i> . 2025 Jul 09; 155:108002. |
| <i>Clin Imaging</i> | Global radiology: Building equitable and effective partnerships with low and middle-income countries. | 40633489 | Kwarteng LA, Lee AY, Sakafu L, Mango VL, Fundikira LS, Lyimo F, Kwikima U, Mushi BP, Van Loon K, Minja FJ. Global radiology: Building equitable and effective partnerships with low and middle-income countries. <i>Clin Imaging</i> . 2025 Jul 07; 125:110559. |
| <i>J Biomech</i> | Soci [©] de Biom [©] canique Young Investigator Award: In silico study of the effects of Left Ventricular Assist Device inflow cannula design and pump unsteady flow on left ventricular hemodynamics. | 40729897 | Chassagne F, L [©] ger C, Straccia A, Bravo CA, Beckman JA, Li S, Mahr C, Aliseda A. Soci [©] de Biom [©] canique Young Investigator Award: In silico study of the effects of Left Ventricular Assist Device inflow cannula design and pump unsteady flow on left ventricular hemodynamics. <i>J Biomech</i> . 2025 Jul 16; 190:112870. |
| <i>Eval Health Prof</i> | A Comprehensive Simulation Study to Evaluate the Effect Size and Study Length Relationship in Single-Group Interrupted Time Series Analysis. | 40662481 | Linden A. A Comprehensive Simulation Study to Evaluate the Effect Size and Study Length Relationship in Single-Group Interrupted Time Series Analysis. <i>Eval Health Prof</i> . 2025 Jul 15; 1632787251361514. |